Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company has discovered and are developing a broad portfolio of product candidates in a variety of indications based on its core platforms, including its non-viral piggyBac deoxyribonucleic acid (DNA) Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and adeno-associated virus (AAV)-based gene delivery technologies. The Company’s product candidate portfolio includes P-BCMA-101, P-PSMA-101, P-BCMA-ALLO1, P-MUC1C-ALL01, Dual CAR, P-OTC-101 and P-MMUT-101.